Vertex Pharmaceuticals FDA Approved SYMDEKO

VRTX chart

Vertex Pharmaceuticals announced that the FDA approved SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor. SYMDEKO is Vertex’s third medicine approved to treat the underlying cause of CF.

Vertex chart looks like a good swing long setup.

VRTX chart

Good looking lower shadows over last few days as downward momentum in the stock fades. The large players volume and Twiggs Money Flow is not as strong as we would like, but both are still positive.

Vertex also has an upcoming PDUFA on the 28th for Tezacaftor as seen here:

Author: Lance Jepsen

For ethical purposes, I try not to hold any position in any stock I profile on unless specifically stated in the article. Owner of Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.

Leave a Reply